Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 1/20 | 0.45 |
| ▸ | PDE1B | Q01064 | 6/20 | 0.42 |
| ▸ | PDE1C | Q14123 | 6/20 | 0.42 |
| ▸ | PDE1A | P54750 | 4/20 | 0.42 |
| ▸ | PDE2A | O00408 | 2/20 | 0.40 |
| ▸ | PDE9A | O76083 | 13/20 | 0.39 |
| ▸ | PDE5A | O76074 | 2/20 | 0.38 |
| ▸ | PDE8A | O60658 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL60960 | 0.93 | GRM1 (0.41) | GRM1PDE1BPDE1CPDE1APDE2A | |
| SCHEMBL61885 | 0.90 | PLK4 (0.45) | GRM1PDE1BPDE1CPDE1APDE2A | |
| SCHEMBL60962 | 0.89 | GRM1 (0.46) | GRM1PDE1BPDE1CPDE1APDE2A | |
| SCHEMBL25876262 | 0.86 | PDE1B (0.40) | GRM1PDE1BPDE1CPDE1APDE2A | |
| SCHEMBL25876057 | 0.85 | GRM1 (0.42) | GRM1PDE1BPDE1CPDE1APDE2A | |
| SCHEMBL60969 | 0.84 | PIK3CA (0.42) | GRM1PDE1BPDE1CPDE1APDE9A | |
| SCHEMBL25876055 | 0.84 | PDE9A (0.36) | GRM1PDE1BPDE1CPDE1APDE2A | |
| SCHEMBL16059106 | 0.83 | GRM1 (0.41) | GRM1PDE1BPDE1CPDE1APDE2A | |
| SCHEMBL60944 | 0.82 | JAK1 (0.37) | GRM1PDE1BPDE1CPDE1APDE2A | |
| SCHEMBL29174753 | 0.81 | GRM1 (0.42) | GRM1PDE1BPDE1CPDE1APDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234954-A1 | COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF | TYK MEDICINES, INC. (CN) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234954-A1 | COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF | RET, ROR1, FGFR3 | GRM1 595/4885PDE1B 397/4885PDE1C 798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.